US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Dyadic International, Inc. - Common Stock (NQ:DYAI)

0.4441 -0.0003 (-0.07%)
Delayed Quote Updated: 3:52 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
From iAccess Alpha
Via ACCESS Newswire
News headline image
Q3 Virtual Investor Summit Presentations Now Available On Demand
From Investor Summit Group
Via ACCESS Newswire
News headline image
Investor Summit | MicroCap Opportunities to Watch - August 26
From Investor Summit Group
Via ACCESS Newswire
Dyadic International Inc (NASDAQ:DYAI) Q1 Report Beats Revenue Expectations but EPS Miss Triggers 28% After-Market Selloff ↗
Via Chartmill
Dyadic International Inc (NASDAQ:DYAI) Reports Q4 2025 Earnings Miss, Stock Dips ↗
Via Chartmill
Topics Earnings
News headline image
Dyadic International (DYAI) Q2 2026 Earnings Call Transcript ↗
Company advances commercialization with initial product shipments and distribution deals. 
Via The Motley Fool
Topics Earnings
MissionIRNewsBreaks – Dyadic International, Inc. (NASDAQ: DYAI) Entered Agreements for $2.9 Million Registered Direct Offering and Private Placement
Via Investor Brand Network
News headline image
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategy 
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (“FBS”) and Scripps Research demonstrates C1's potential to accelerate vaccine and monoclonal antibody development, expand... 
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Announces Continued Listing on the Nasdaq Capital Market
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform 
From Dyadic International, Inc.
Via GlobeNewswire
Which stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding 
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Expands IP Protection and Business Development Activities in Japan
Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions 
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial... 
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic (DYAI) Q1 2026 Earnings Call Transcript ↗
Dyadic (DYAI) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic Production 
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic (DYAI) Q4 2025 Earnings Call Transcript ↗
Dyadic (DYAI) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
From Dyadic International, Inc.
Via GlobeNewswire
News headline image
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
From Dyadic International, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >